Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall survival improved by five months in first-line metastatic TNBC. Objective ...
Senators disclosed Taubenberger’s exit during a hearing after he failed to appear as a scheduled witness, and NIH leadership did not publicly refute the claim. Leadership vacancy was framed as ...
Accelerating select programs while slowing others has widened outcome variance, making regulatory predictability the dominant operational and financing constraint. Companies increasingly demand ...
David Crean, chief business officer at MedicNova, highlights bifurcation in regulatory processes at FDA. Marty Makary is the latest key leader at HHS to leave their role over the past two years. Aside ...
In today's Pharmaceutical Executive Daily, Eli Lilly announces a deal worth up to $202 million for Engage Biologics and its ...
The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...
In April, FDA announced plans for a pilot program to allow for real-time data review during clinical trials. 1 The program ...
This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...
Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results